Today is 2020-07-15

Relationship between aneurysm wall enhancement and therapeutic prognosis in patients with unruptured intracranial aneurysms: A high-resolution vessel wall magnetic resonance imaging(VW-MRI)study
download

注册号:

Registration number:

ChiCTR2000031292 

最近更新日期:

Date of Last Refreshed on:

2020-04-01 

注册时间:

Date of Registration:

2020-03-26 

注册号状态:

补注册  

Registration Status:

Retrospective registration  

注册题目:

请尽快在IPD平台上传原始数据。 基于高分辨血管壁磁共振(VW-MRI)及影像组学评估颅内动脉瘤手术相关预后的临床研究 

Public title:

Relationship between aneurysm wall enhancement and therapeutic prognosis in patients with unruptured intracranial aneurysms: A high-resolution vessel wall magnetic resonance imaging(VW-MRI)study 

注册题目简写:

 

English Acronym:

 

研究课题的正式科学名称:

基于高分辨血管壁磁共振(VW-MRI)及影像组学评估颅内动脉瘤手术相关预后的临床研究 

Scientific title:

Relationship between aneurysm wall enhancement and therapeutic prognosis in patients with unruptured intracranial aneurysms: A high-resolution vessel wall magnetic resonance imaging(VW-MRI) study 

研究课题代号(代码):

Study subject ID:

81571102; 2017BR006; 2018SHZDZX03 

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

 

申请注册联系人:

全凯 

研究负责人:

朱巍 

Applicant:

Kai Quan 

Study leader:

Wei Zhu 

申请注册联系人电话:

Applicant telephone:

+86 18930063601 

研究负责人电话:

Study leader's telephone:

+86 18621120936 

申请注册联系人传真 :

Applicant Fax:

 

研究负责人传真:

Study leader's fax:

 

申请注册联系人电子邮件:

Applicant E-mail:

abcmo@163.com 

研究负责人电子邮件:

Study leader's E-mail:

drzhuwei@fudan.edu.cn 

申请单位网址(自愿提供):

Applicant website(voluntary supply):

 

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

 

申请注册联系人通讯地址:

上海市静安区乌鲁木齐中路12号华山医院6号楼13楼医生办公室 

研究负责人通讯地址:

上海市静安区乌鲁木齐中路12号华山医院6号楼13楼医生办公室 

Applicant address:

12 Middle Wulumuqi Road, Jing'an District, Shanghai, China 

Study leader's address:

12 Middle Wulumuqi Road, Jing'an District, Shanghai, China 

申请注册联系人邮政编码:

Applicant postcode:

200040 

研究负责人邮政编码:

Study leader's postcode:

 

申请人所在单位:

复旦大学附属华山医院神经外科 

Applicant's institution:

Department of Neurosurgery, Huashan Hospital, Fudan University 

是否获伦理委员会批准:

是 

Approved by ethic committee:

Yes 

伦理委员会批件文号:

Approved No. of ethic committee:

IRB 2017- D386 

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

复旦大学附属华山医院伦理审查委员会 

Name of the ethic committee:

ethics committee of Huashan Hospital, Fudan University 

伦理委员会批准日期:

Date of approved by ethic committee:

2017-12-29 

伦理委员会联系人:

吴翠云 

Contact Name of the ethic committee:

Wu Cuiyun 

伦理委员会联系地址:

上海市静安区乌鲁木齐中路12号复旦大学附属华山医院门诊9楼伦理审查委员会办公室 

Contact Address of the ethic committee:

12 Middle Wulumuqi Road, Jing'an District, Shanghai, China 

伦理委员会联系人电话:

Contact phone of the ethic committee:

 

伦理委员会联系人邮箱:

Contact email of the ethic committee:

 

研究实施负责(组长)单位:

复旦大学附属华山医院 

Primary sponsor:

Huashan Hospital, Fudan University 

研究实施负责(组长)单位地址:

上海市静安区乌鲁木齐中路12号复旦大学附属华山医院 

Primary sponsor's address:

12 Middle Wulumuqi Road, Jing'an District, Shanghai, China 

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属华山医院

具体地址:

上海市静安区乌鲁木齐中路12号

Institution
hospital:

Huashan Hospital, Fudan University

Address:

12 Wulumuqi Zhong Road

经费或物资来源:

国自然面上项目(81571102)、上海市卫生计生系统百人计划(2017BR006)、上海市“脑与类脑智能”市级重大科技专项资助(No.2018SHZDZX03)和张江实验室 

Source(s) of funding:

National Natural Science Foundation of China (81571102), the outstanding academic leaders program of Shanghai Municipal Commission of Health and Family Planning (No. 2017BR006), Shanghai Municipal  

研究疾病:

脑动脉瘤 

Target disease:

Intracranial aneurysm 

研究疾病代码:

 

Target disease code:

 

研究类型:

预后研究 

Study type:

Prognosis study 

研究所处阶段:

探索性研究/预试验 

Study phase:

研究目的:

高分辨血管壁磁共振(VW-MRI)是一种新的评估颅内未破裂动脉瘤的影像技术,然而其影像学特征与实际病理学改变目前尚不清楚。以往研究表明:瘤壁强化代表动脉瘤高进展/破裂风险。我们的前期研究已证明高分辨VW-MRI不同强化类型分别反映动脉瘤瘤壁高炎症水平及局部斑块形成,对于颅内未破裂动脉瘤的干预时机/治疗选择具有重要意义。但目前研究结果主要限于队列形态学研究,缺乏大样本数据支持。在本研究中,我们将利用影像组学技术建立高分辨VW-MRI颅内未破裂动脉瘤数字化、可视化影像学模型,从而探索高分辨VW-MRI评估颅内未破裂动脉瘤瘤壁结构及治疗预后的作用。 

Objectives of Study:

High-resolution vessel wall magnetic resonance imaging(VW-MRI)is a promising technique for assessing wall structures of unruptured intracranial aneurysms(UIAs). However, the relationship between aneurysmal high-resolution vessel wall magnetic resonance imaging features and their histopathologic mechanism remains poorly understood. Previous studies demonstrated that gadolinium-enhancement of the aneurysm wall on VW-MRI reflects aneurysm wall inflammation and may therefore be a marker for aneurysm instability. The previous research work of our team show Different high-resolution VW-MRI enhancement features may represent variable inflammation status of a UIA wall, and we assume that high-resolution VW-MRI can aid the surgical planning for UIAs. However, the current research results are mainly limited to cohort studies and lack of large scale investigations. In this study, we will use radiomics to establish a digital, visual imaging model of high-resolution VW-MRI on UIAs, and exploring the role of high-resolution VW-MRI in evaluating the structure and therapeutic prognosis of UIAs. 

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

研究设计:

队列研究 

Study design:

Cohort study 

纳入标准:

1、年龄在18-75岁之间,(男女不限); 2、所有患者在评估前均行MRA/CTA/DSA确诊颅内动脉瘤; 3、6月内未发生蛛网膜下腔出血; 4、患者生活自理,KPS评分>60分; 5、患者家属签署知情同意书并配合临床治疗及随访; 6、患者未参加其他类似研究。 

Inclusion criteria

1. Aged 18 to 75 years; 2. Cerebral aneurysm confirmed by DSA, CTA and MRA; 3. Patients without subarachnoid hemorrhage within 6 months; 4. Patients can take care of themselves with a KPS scale (mRS)>60 ; 5. Patients' families will sign informed consent and cooperate with clinical treatment and follow-up; 6. Patients do not participate in other similar studies. 

排除标准:

1、严重器质性疾病,如急性心梗死、肾功能障碍、恶性肿瘤等或者KPS评分≤60分者; 2、妊娠或哺乳期妇女; 3、合并其他系统难治性疾病如自身免疫性疾病、血液病等患者; 4、拒绝手术或介入栓塞治疗的患者。 

Exclusion criteria:

1. Patients with other systemic refractory disease, such as acute heart infarction, renal dysfunction and malignant tumor, etc, or KPS scale (mRS)<=60; 2. Pregnant or lactating women, or a positive pregnancy test on admission; 3. Patients with other systemic diseases, such autoimmune disease or blood disorder 4. Patients refuse surgery or interventional embolization. 

研究实施时间:

Study execute time:

From2017-12-26To 2021-12-31 

干预措施:

Interventions:

组别:

1组

样本量:

300

Group:

Group 1

Sample size:

干预措施:

开颅夹闭

干预措施代码:

Intervention:

Surgical clipping

Intervention code:

组别:

2组

样本量:

400

Group:

Group 2

Sample size:

干预措施:

介入栓塞

干预措施代码:

Intervention:

Endovascular embolization

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国 

省(直辖市):

上海 

市(区县):

 

Country:

China 

Province:

Shanghai 

City:

 

单位(医院):

复旦大学附属华山医院 

单位级别:

三级甲等 

Institution
hospital:

Huashan Hospital, Fudan University  

Level of the institution:

Tertiary A Hospital 

国家:

中国 

省(直辖市):

福建 

市(区县):

 

Country:

China 

Province:

Fujian 

City:

 

单位(医院):

福建医科大学附属第一医院 

单位级别:

三甲医院 

Institution
hospital:

First Affiliated Hospital of Fujian Medical University  

Level of the institution:

Tertiary hospital 

国家:

中国 

省(直辖市):

重庆 

市(区县):

 

Country:

China 

Province:

Chongqing 

City:

 

单位(医院):

重庆医科大学附属第一医院 

单位级别:

三甲医院 

Institution
hospital:

First Affiliated Hospital of Chongqing Medical University  

Level of the institution:

Tertiary hospital 

国家:

中国 

省(直辖市):

吉林 

市(区县):

 

Country:

China 

Province:

Jilin 

City:

 

单位(医院):

吉林大学第一医院 

单位级别:

三甲医院 

Institution
hospital:

First Affiliated Hospital of Jilin University  

Level of the institution:

Tertiary hospital 

测量指标:

Outcomes:

指标中文名:

GOS评分

指标类型:

主要指标 

Outcome:

GOS score

Type:

Primary indicator 

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

mRs评分

指标类型:

主要指标 

Outcome:

mRS score

Type:

Primary indicator 

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

残留/复发率

指标类型:

主要指标 

Outcome:

residual/recurrence rate

Type:

Primary indicator 

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

其他神经功能缺失

指标类型:

次要指标 

Outcome:

Other neurological deficit

Type:

Secondary indicator 

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

DWI信号

指标类型:

次要指标 

Outcome:

DWIsignal

Type:

Secondary indicator 

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

动脉瘤壁

组织:

脑血管

Sample Name:

aneurysmal sac

Tissue:

Cerebral artery

人体标本去向

使用后保存 

说明

蜡块保存20年

Fate of sample:

Preservation after use 

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

N/A

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

盲法:

未说明

Blinding:

Not stated

试验完成后的统计结果(上传文件):

Calculated Results ater
the Study Completed(upload file):

原始数据公开时间:

The time of sharing IPD:

Within six months after the trial complete

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

中国临床试验中心

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

www.chictr.org.cn

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表(Case Record Form, CRF)

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据管理委员会:

Data Managemen Committee:

有/Yes

注册人:

Name of Registration:

 2020-03-26
return list